The evolutionary safety of mutagenic drugs should be assessed before drug approval

Gabriela Lobinska; Vyacheslav Tretyachenko; Orna Dahan; Martin A. Nowak; Yitzhak Pilpel

doi:10.1371/journal.pbio.3002570

The evolutionary safety of mutagenic drugs should be assessed before drug approval

Gabriela Lobinska
, Vyacheslav Tretyachenko
, Orna Dahan
, Martin A. Nowak
, Yitzhak Pilpel

Department of Molecular Genetics

Weizmann Institute of Science

Research output: Contribution to journal › Article › peer-review

Abstract

Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.

Original language	English
Article number	e3002570
Journal	PLOS Biology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1371/journal.pbio.3002570
State	Published - 15 Mar 2024

ASJC Scopus subject areas

General Neuroscience
General Biochemistry,Genetics and Molecular Biology
General Immunology and Microbiology
General Agricultural and Biological Sciences

Access to Document

10.1371/journal.pbio.3002570License: CC BY

Cite this

@article{4fd60f84f81d41319491e571877b440f,

title = "The evolutionary safety of mutagenic drugs should be assessed before drug approval",

abstract = "Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.",

author = "Gabriela Lobinska and Vyacheslav Tretyachenko and Orna Dahan and Nowak, \{Martin A.\} and Yitzhak Pilpel",

note = "This work was supported by the Kimmel Foundation (YP) and the Minerva Center on Live Emulation of Evolution in the Lab (YP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.",

year = "2024",

month = mar,

day = "15",

doi = "10.1371/journal.pbio.3002570",

language = "الإنجليزيّة",

volume = "22",

journal = "PLOS Biology",

issn = "1544-9173",

publisher = "Public Library of Science",

number = "3",

}

TY - JOUR

T1 - The evolutionary safety of mutagenic drugs should be assessed before drug approval

AU - Lobinska, Gabriela

AU - Tretyachenko, Vyacheslav

AU - Dahan, Orna

AU - Nowak, Martin A.

AU - Pilpel, Yitzhak

N1 - This work was supported by the Kimmel Foundation (YP) and the Minerva Center on Live Emulation of Evolution in the Lab (YP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

PY - 2024/3/15

Y1 - 2024/3/15

N2 - Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.

AB - Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.

UR - https://www.scopus.com/pages/publications/85188011622

U2 - 10.1371/journal.pbio.3002570

DO - 10.1371/journal.pbio.3002570

M3 - مقالة

C2 - 38489394

SN - 1544-9173

VL - 22

JO - PLOS Biology

JF - PLOS Biology

IS - 3

M1 - e3002570

ER -

The evolutionary safety of mutagenic drugs should be assessed before drug approval

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this